However, through enhancing nitric oxide (NO)–cyclic guanosine monophosphate (cGMP) signaling, PDE5 inhibitors improve vascular compliance, cerebral blood flow, and mitochondrial function, addressing core pathways implicated in AD and cognitive decline [50]. The gene discussed is PDE5A; the disease is Alzheimer disease.